BioCorRx Inc. (BICX)
| Previous close | 0.8200 |
| Open | 0.9000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.8200 - 0.8200 |
| 52-week range | 0.6720 - 2.2200 |
| Volume | |
| Avg. volume | 1,058 |
| Market cap | 7.229M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4500 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireBioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO). The USPTO has issued U.S. Patent No. 11,793,801 entitled, “Treatment of Pain and Neurological Conditio
- GlobeNewswire
BioCorRx Reports Business Update for 2023
ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantab
- GlobeNewswire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), under award number U01DA059994 for the development of BICX104, a subc
